itil-168
Cell therapyexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 7, 2021 (NCT05050006)
Timeline
Indications
Mechanism of action
- Tumor antigensImmunity, passive
immunity, passive - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05393635 | Phase 1 | Aug 31, 2022 | Instil Bio, Instil Bio, Inc. |
| NCT05050006 | Phase 2 | Oct 7, 2021 | Instil Bio, Instil Bio, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Instil Bio | For profit | 2 | 2 | 2 | 2021 |
| Instil Bio, Inc. | For profit | 2 | 0 | 2 | 2021 |
2 organizations
Page 1 / 1